Skip Navigation
Skip to contents

CPP : Cardiovascular Prevention and Pharmacotherapy

Sumissioin : submit your manuscript

Previous issues

Page Path
HOME > Browse articles > Previous issues
3 Previous issues
Article category
Volume 3(1); January 2021
Prev issue Next issue
Special Articles
Tafamidis for Cardiac Transthyretin Amyloidosis
Darae Kim, Jin-Oh Choi, Eun-Seok Jeon
Cardiovasc Prev Pharmacother. 2021;3(1):1-9.   Published online January 31, 2021
  • 3,337 View
  • 55 Download
  • 1 Citations
Abstract PDF
Transthyretin amyloid (ATTR) cardiomyopathy is a progressive disease caused by the infiltration of ATTR fibrils in the myocardium. Although it is a rare disease, ATTR cardiomyopathy is an important cause of heart failure with preserved ejection fraction, and its incidence is increasing due to improved diagnostic imaging tools. There has been a breakthrough in the field of transthyretin amyloidosis, which opens a new therapeutic door for the patients. In this review, an overview of tafamidis therapy in ATTR cardiomyopathy with recent results from clinical trials will be discussed.


Citations to this article as recorded by  
  • Multimodal Imaging and Biomarkers in Cardiac Amyloidosis
    Mi-Hyang Jung, Suyon Chang, Eun Ji Han, Jong-Chan Youn
    Diagnostics.2022; 12(3): 627.     CrossRef
Vasopressin Receptor Antagonist, Tolvaptan, for Treating Hyponatremia in Patients with Heart Failure
Kyung-Jin Kim
Cardiovasc Prev Pharmacother. 2021;3(1):10-14.   Published online January 31, 2021
  • 1,808 View
  • 45 Download
Abstract PDF
Hyponatremia is common in hospital setting in patients with heart failure and is associated with increased morbidity and mortality. However, despite these complications, appropriate treatment strategies other than established therapies such as hypertonic saline, loop diuretics, and fluid restriction are limited. Tolvaptan, a vasopressin receptor antagonist, has aquaretic effects that excrete free water and dilutes urine, thereby increasing serum sodium concentration. This new approach might be a landmark in the treatment of hyponatremia as there is a lack of controlled studies in this field. However, regardless of the associated advantage, tolvaptan is recommended to be used for less than 30 days owing to the possibility of liver injury. This study is aimed to present the clinical use of tolvaptan for hyponatremia in patients with heart failure.
Methods for Evaluating the Accuracy of Diagnostic Tests
Chi-Yeon Lim
Cardiovasc Prev Pharmacother. 2021;3(1):15-20.   Published online January 31, 2021
  • 1,721 View
  • 61 Download
Abstract PDF
The accuracy of a diagnostic test should be evaluated before it is used in clinical situations. The sensitivity, specificity, and the trade-off between the 2 need to be considered. Sensitivity and specificity in diagnostic tests depend on the selection of cut-off values, and appropriate cut-off values can be arrived at by analyzing the receiver operating characteristic curve. In actual clinical setting, it is often difficult to obtain an appropriate gold standard for diagnosis, and in this case, consent is required as well. In this article, we summarize the basic concepts and methods for evaluating the performance of diagnostic tests.

CPP : Cardiovascular Prevention and Pharmacotherapy